Literature DB >> 20696944

Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education.

Niklas K Björkström1, Peggy Riese, Frank Heuts, Sandra Andersson, Cyril Fauriat, Martin A Ivarsson, Andreas T Björklund, Malin Flodström-Tullberg, Jakob Michaëlsson, Martin E Rottenberg, Carlos A Guzmán, Hans-Gustaf Ljunggren, Karl-Johan Malmberg.   

Abstract

Natural killer (NK) cells are lymphocytes of the innate immune system that, following differentiation from CD56(bright) to CD56(dim) cells, have been thought to retain fixed functional and phenotypic properties throughout their lifespan. In contrast to this notion, we here show that CD56(dim) NK cells continue to differentiate. During this process, they lose expression of NKG2A, sequentially acquire inhibitory killer cell inhibitory immunoglobulin-like receptors and CD57, change their expression patterns of homing molecules, and display a gradual decline in proliferative capacity. All cellular intermediates of this process are represented in varying proportions at steady state and appear, over time, during the reconstitution of the immune system, as demonstrated in humanized mice and in patients undergoing hematopoietic stem cell transplantation. CD56(dim) NK-cell differentiation, and the associated functional imprint, occurs independently of NK-cell education by interactions with self-human leukocyte antigen class I ligands and is an essential part of the formation of human NK-cell repertoires.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20696944     DOI: 10.1182/blood-2010-04-281675

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  306 in total

1.  Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function.

Authors:  Bree Foley; Sarah Cooley; Michael R Verneris; Michelle Pitt; Julie Curtsinger; Xianghua Luo; Sandra Lopez-Vergès; Lewis L Lanier; Daniel Weisdorf; Jeffrey S Miller
Journal:  Blood       Date:  2011-12-16       Impact factor: 22.113

2.  Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy.

Authors:  Caroline Veuillen; Thérèse Aurran-Schleinitz; Rémy Castellano; Jérôme Rey; Françoise Mallet; Florence Orlanducci; Laurent Pouyet; Sylvaine Just-Landi; Diane Coso; Vadim Ivanov; Xavier Carcopino; Réda Bouabdallah; Yves Collette; Cyril Fauriat; Daniel Olive
Journal:  J Clin Immunol       Date:  2012-02-09       Impact factor: 8.317

Review 3.  Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.

Authors:  Martha Luevano; Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

4.  CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset.

Authors:  Sandra Lopez-Vergès; Jeffrey M Milush; Suchitra Pandey; Vanessa A York; Janice Arakawa-Hoyt; Hanspeter Pircher; Philip J Norris; Douglas F Nixon; Lewis L Lanier
Journal:  Blood       Date:  2010-08-23       Impact factor: 22.113

Review 5.  Harnessing adaptive natural killer cells in cancer immunotherapy.

Authors:  Lisa L Liu; Aline Pfefferle; Vincent Oei Yi Sheng; Andreas T Björklund; Vivien Béziat; Jodie P Goodridge; Karl-Johan Malmberg
Journal:  Mol Oncol       Date:  2015-10-20       Impact factor: 6.603

6.  Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.

Authors:  Sawa Ito; Catherine M Bollard; Mattias Carlsten; Jan Joseph Melenhorst; Angélique Biancotto; Ena Wang; Jinguo Chen; Yuri Kotliarov; Foo Cheung; Zhi Xie; Francesco Marincola; Kazushi Tanimoto; Minoo Battiwalla; Matthew J Olnes; Shira Perl; Paula Schum; Thomas E Hughes; Keyvan Keyvanfar; Nancy Hensel; Pawel Muranski; Neal S Young; A John Barrett
Journal:  Mol Ther       Date:  2014-04-01       Impact factor: 11.454

7.  IL-12, IL-15, and IL-18 pre-activated NK cells target resistant T cell acute lymphoblastic leukemia and delay leukemia development in vivo.

Authors:  Margherita Boieri; Aina Ulvmoen; Amanda Sudworth; Clare Lendrem; Matthew Collin; Anne M Dickinson; Lise Kveberg; Marit Inngjerdingen
Journal:  Oncoimmunology       Date:  2017-01-17       Impact factor: 8.110

8.  NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs.

Authors:  Vivien Béziat; Lisa L Liu; Jenny-Ann Malmberg; Martin A Ivarsson; Ebba Sohlberg; Andreas T Björklund; Christelle Retière; Eva Sverremark-Ekström; James Traherne; Per Ljungman; Marie Schaffer; David A Price; John Trowsdale; Jakob Michaëlsson; Hans-Gustaf Ljunggren; Karl-Johan Malmberg
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

9.  Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.

Authors:  Jeffrey S Miller; Cliona M Rooney; Julie Curtsinger; Ron McElmurry; Valarie McCullar; Michael R Verneris; Natalia Lapteva; David McKenna; John E Wagner; Bruce R Blazar; Jakub Tolar
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-09       Impact factor: 5.742

10.  Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells.

Authors:  Jeffrey W Leong; Julie M Chase; Rizwan Romee; Stephanie E Schneider; Ryan P Sullivan; Megan A Cooper; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-13       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.